Uromac®, is a sterile solution of hyaluronic acid for bladder irrigation, available as 100 mg of hyaluronic acid in a 50 milliliter vial. The product is sterile and single use; it should not be reused under any circumstances.



Uromac® functions as a protective coating for the inner mucosa of the bladder and urethral mucosa. It is a revolution in the use of the sodium salt of hyaluronic acid, a polysaccharide widely present in the tissues of the human body, where it performs diverse and fundamental biological functions. Thanks to its protective and film-forming properties, it fosters a more natural cellular regeneration of the mucosa.

Uromac® is well tolerated by the body, does not produce unwanted side effects and has no specific contraindications.

The integrity of the epithelial tissue that lines the bladder mucosa is essential to ensure the natural protective and barrier functions that the tissue presents against the aggressions of pathogens, microorganisms and toxic substances.

Uromac®, is low molecular weight and very low viscosity hyaluronic acid. Thanks to these properties, it has been developed to function as an adjunct in the processes of reepithelialization of the bladder and urethral mucosa.

Below you can download the promotional brochure with all the information you need about Uromac®

ZIP download (5,331 kb)


Uromac® is a medicinal product composed of hyaluronic acid, indicated as a protector of the bladder and urethral mucosa and capable of promoting the physiological repair of mucosal lesions.

Uromac® is indicated in radiotherapy both prophylactically and as an adjuvant for the repair of the bladder mucosa in patients exposed to radiation. It is also indicated in urology to promote the repair of damaged bladder and urethral mucous membranes, in gynecology for invasive gynecological examinations and in surgeries where said mucous membranes can suffer damage.


Bibliographic References

  1. Pimentel AA y cols. Efectos del ácido hialurónico sobre el mecanismo de la cicatrización en la anastomosis de la uretra. Bol Col. Mexicano de Urología. 2001 Ene-Mar. 27(1):26-31
  2. Morales A, Emerson L, Nickel JC, Lundie M. Intravesical hyaluronic acid in the treatment of refractory interstitial cystitis. The Journal of Urology. 1996 Jul; 156:45-48
  3. Takahashi K, Takeuchi J, Takahashi T, Miyauchi S, Horie K, Uchiyama Y. Effects of the sodium hyaluronate on epithelial healing of the vesical mucosa and vesical fibrosis in rabbits with acetic acid induced cistitits. The Journal of Urology. 2001 Aug; 166:710-713
  4. Erickson DR, Sheykhnazari M, Ordile S, Bhavanandan VP. Increased urinari hyaluronic acid and interstitial cystitis. The Journal of Urology. 1998 Oct; 160:1282-1284
  5. Toft BR, Nordling J. Recent developtments of intravesical therapy of painful bladder sindrome/interstitial cistitis: a review. Current Opinion in Urology. 2006; 16:268-272
  6. Cipe FE, Soygür T, Doğu F, Erdoğan O, Bozdoğan G, Ikincioğullari A. Late onset hemorragia cistitis in a hematopoietic item recipient: Treatment with intravesical hyaluronic acid. Pediatr. Transplantation 2010; 14:E79-E82

C/ Azcárraga, 12 A, P-2, 3ºC 33010 Oviedo. Spain.

Legal warning Design and development by [Q]